Clinical Trial

Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

Study acronym: BICEP
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-10.
Trial Details
NCT Number NCT07226947
Lead Sponsor Massachusetts General Hospital
Collaborators: Samsung
Conditions Obesity, Body Composition
Enrollment 100 participants
Start Date 2025-11-24
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-30